QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NYSE:DGX

Quest Diagnostics - DGX Stock Forecast, Price & News

$135.39
+1.07 (+0.80%)
(As of 03/23/2023 04:32 PM ET)
Add
Compare
Today's Range
$133.19
$135.42
50-Day Range
$131.53
$148.64
52-Week Range
$120.40
$158.34
Volume
2.43 million shs
Average Volume
1.21 million shs
Market Capitalization
$15.07 billion
P/E Ratio
17.09
Dividend Yield
1.95%
Price Target
$150.91

Quest Diagnostics MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
12.2% Upside
$150.91 Price Target
Short Interest
Healthy
3.01% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.56mentions of Quest Diagnostics in the last 14 days
Based on 26 Articles This Week
Insider Trading
Selling Shares
$200,109 Sold Last Quarter
Proj. Earnings Growth
5.07%
From $8.68 to $9.12 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.99 out of 5 stars

Medical Sector

35th out of 986 stocks

Medical Laboratories Industry

2nd out of 26 stocks


DGX stock logo

About Quest Diagnostics (NYSE:DGX) Stock

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Stock News Headlines

The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Quest Diagnostics Remains A Solid Long-Term Company
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Mizuho Reiterates Buy Rating for Quest Diagnostics (NYSE:DGX)
Quest Diagnostics (NYSE:DGX) Releases FY23 Earnings Guidance
Analyst Expectations for Quest Diagnostics's Future
Keeping Kids and Families Healthy and Active
See More Headlines
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Company Calendar

Ex-Dividend for 2/1 Dividend
1/17/2023
Dividend Payable
2/01/2023
Last Earnings
2/02/2023
Today
3/23/2023
Ex-Dividend for 4/24 Dividend
4/06/2023
Next Earnings (Estimated)
4/20/2023
Dividend Payable
4/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
74834L10
Employees
49,000
Year Founded
1967

Price Target and Rating

Average Stock Price Forecast
$150.91
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$125.00
Forecasted Upside/Downside
+12.0%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

Net Income
$946 million
Pretax Margin
12.50%

Debt

Sales & Book Value

Annual Sales
$9.88 billion
Cash Flow
$14.39 per share
Book Value
$52.07 per share

Miscellaneous

Free Float
109,431,000
Market Cap
$14.99 billion
Optionable
Optionable
Beta
0.95

Social Links


Key Executives

  • James E. Davis
    President, Chief Executive Officer & Director
  • Sam A. Samad
    Chief Financial Officer & Executive Vice President
  • Jay G. Wohlgemuth
    Chief Medical Officer, Senior VP-R&D, Medical
  • Gabrielle Wolfson
    SVP, Chief Information & Digital Officer
  • Timothy U. Sharpe
    Vice President-Compliance













DGX Stock - Frequently Asked Questions

Should I buy or sell Quest Diagnostics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View DGX analyst ratings
or view top-rated stocks.

What is Quest Diagnostics' stock price forecast for 2023?

10 analysts have issued 12 month target prices for Quest Diagnostics' stock. Their DGX share price forecasts range from $125.00 to $165.00. On average, they anticipate the company's stock price to reach $150.91 in the next twelve months. This suggests a possible upside of 11.5% from the stock's current price.
View analysts price targets for DGX
or view top-rated stocks among Wall Street analysts.

How have DGX shares performed in 2023?

Quest Diagnostics' stock was trading at $156.44 at the beginning of the year. Since then, DGX stock has decreased by 13.5% and is now trading at $135.39.
View the best growth stocks for 2023 here
.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a increase in short interest in February. As of February 28th, there was short interest totaling 3,320,000 shares, an increase of 8.9% from the February 13th total of 3,050,000 shares. Based on an average daily trading volume, of 1,130,000 shares, the days-to-cover ratio is presently 2.9 days. Currently, 3.0% of the shares of the company are sold short.
View Quest Diagnostics' Short Interest
.

When is Quest Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 20th 2023.
View our DGX earnings forecast
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) announced its quarterly earnings data on Thursday, February, 2nd. The medical research company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $1.90 by $0.08. The medical research company had revenue of $2.33 billion for the quarter, compared to the consensus estimate of $2.26 billion. Quest Diagnostics had a trailing twelve-month return on equity of 18.84% and a net margin of 9.57%. The company's revenue for the quarter was down 15.0% on a year-over-year basis. During the same quarter last year, the company posted $3.33 earnings per share.
Read the conference call transcript
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Thursday, February 2nd. Stockholders of record on Monday, April 10th will be paid a dividend of $0.71 per share on Monday, April 24th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.10%. The ex-dividend date is Thursday, April 6th. This is a boost from the stock's previous quarterly dividend of $0.66.
Read our dividend analysis for DGX
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics (NYSE:DGX) pays an annual dividend of $2.64 per share and currently has a dividend yield of 1.99%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 33.33%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DGX will have a dividend payout ratio of 28.95% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DGX.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics announced that its Board of Directors has approved a share repurchase program on Thursday, February 2nd 2023, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 6% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board of directors believes its shares are undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY23 earnings guidance on Thursday, March, 16th. The company provided earnings per share (EPS) guidance of $8.40-9.00 for the period, compared to the consensus EPS estimate of $8.71. The company issued revenue guidance of $8.83 billion to $9.03 billion, compared to the consensus revenue estimate of $8.98 billion.

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (2.93%), Victory Capital Management Inc. (2.85%), Geode Capital Management LLC (2.07%), Dimensional Fund Advisors LP (1.79%), Morgan Stanley (1.66%) and Davis Selected Advisers (1.61%). Insiders that own company stock include Catherine T Doherty, Daniel Stanzione, Gail R Wilensky, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe, Stephen H Rusckowski, Stephen H Rusckowski and Timothy M Ring.
View institutional ownership trends
.

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $135.39.

How much money does Quest Diagnostics make?

Quest Diagnostics (NYSE:DGX) has a market capitalization of $15.07 billion and generates $9.88 billion in revenue each year. The medical research company earns $946 million in net income (profit) each year or $7.92 on an earnings per share basis.

How many employees does Quest Diagnostics have?

The company employs 49,000 workers across the globe.

Does Quest Diagnostics have any subsidiaries?
The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).
Read More
How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The official website for the company is www.questdiagnostics.com. The medical research company can be reached via phone at (973) 520-2700, via email at investor@questdiagnostics.com, or via fax at 201-462-4169.

This page (NYSE:DGX) was last updated on 3/23/2023 by MarketBeat.com Staff